Details for Patent: 9,175,017

Which drugs does patent 9,175,017 protect, and when does it expire?

Patent 9,175,017 protects NINLARO and is included in one NDA.

This patent has one hundred and twenty-three patent family members in thirty-seven countries.

Summary for Patent: 9,175,017

Title:	Boronate ester compounds and pharmaceutical compositions thereof
Abstract:	The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Inventor(s):	Elliott; Eric L. (Brighton, MA), Ferdous; Abu J. (Winchester, MA), Kaufman; Michael J. (Lexington, MA), Komar; Sonja A. (Belmont, MA), Mazaik; Debra L. (Holliston, MA), McCubbin; Quentin J. (Belmont, MA), Nguyen; Phuong M. (Cambridge, MA), Palaniappan; Vaithianathan (Andover, MA), Skwierczynski; Raymond D. (Andover, MA), Truong; Nobel T. (Milford, MA), Varga; Csanad M. (Newton, MA), Zawaneh; Peter N. (Cambridge, MA)
Assignee:
Application Number:	14/449,275
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,175,017
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form; Delivery;

Drugs Protected by US Patent 9,175,017

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No						USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-002	Nov 20, 2015		RX	Yes	No						USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-003	Nov 20, 2015		RX	Yes	Yes						USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

International Family Members for US Patent 9,175,017

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072162
Argentina	095554
Argentina	095566
Argentina	100011
Australia	2009260778